| 2.05 -0.06 (-2.84%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.07  |
1-year : | 3.51 |
| Resists | First : | 2.63 |
Second : | 3 |
| Pivot price | 2.36 |
|||
| Supports | First : | 2.01 |
Second : | 1.68 |
| MAs | MA(5) : | 2.16 |
MA(20) : | 2.4 |
| MA(100) : | 1.94  |
MA(250) : | 1.27 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 5.4 |
D(3) : | 7.1 |
| RSI | RSI(14): 37.9 |
|||
| 52-week | High : | 3.06 | Low : | 0.35 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ IVVD ] has closed above bottom band by 1.0%. Bollinger Bands are 21% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.16 - 2.18 | 2.18 - 2.19 |
| Low: | 1.99 - 2 | 2 - 2.01 |
| Close: | 2.03 - 2.05 | 2.05 - 2.07 |
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Sat, 24 Jan 2026
How Recent Price Target Resets Are Rewriting The Story For Invivyd (IVVD) - Yahoo Finance
Thu, 22 Jan 2026
Lindsey Vonn joins Invivyd to help Americans understand antibodies - Stock Titan
Thu, 22 Jan 2026
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention - Sahm
Mon, 19 Jan 2026
Short Interest in Invivyd, Inc. (NASDAQ:IVVD) Grows By 24.4% - MarketBeat
Thu, 15 Jan 2026
Invivyd, Inc. (NASDAQ:IVVD) Given Average Rating of "Hold" by Brokerages - MarketBeat
Wed, 14 Jan 2026
Invivyd (IVVD) Reports Strong Q4 Growth, Advances COVID Antibody to Phase 3 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 282 (M) |
| Shares Float | 138 (M) |
| Held by Insiders | 11.4 (%) |
| Held by Institutions | 74.1 (%) |
| Shares Short | 35,610 (K) |
| Shares Short P.Month | 28,250 (K) |
| EPS | -0.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.43 |
| Profit Margin | -119.7 % |
| Operating Margin | -84 % |
| Return on Assets (ttm) | -25.9 % |
| Return on Equity (ttm) | -68 % |
| Qtrly Rev. Growth | 41.2 % |
| Gross Profit (p.s.) | 0.16 |
| Sales Per Share | 0.17 |
| EBITDA (p.s.) | -0.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -80 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -4.56 |
| PEG Ratio | 0 |
| Price to Book value | 4.76 |
| Price to Sales | 11.55 |
| Price to Cash Flow | -7.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|